5 enrolling by invitation. 5 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Enrolling by invitation 5 |
| Phase 2 | 2 | Enrolling by invitation 2 |
Follow Liver Diseases: new trials by email Literature Review of Liver Diseases trials Research Report on Liver Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-10-28 |
| A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics Prednisone, UDCA (Ursodeoxycholic acid) - Primary Biliary Cholangitis (PBC) | Phase 2 / Phase 3 | Enrolling by invitation | Han Ying | 244 | 2024-10-30 | 2026-10-29 |
| Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy GODEX, Placebo - Non-Alcoholic Fatty Liver Disease | Phase 3 | Enrolling by invitation | Yoon Jun Kim | 196 | 2023-09-25 | 2023-12-01 |
| HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP DISC-1459 - Erythropoietic Protoporphyria | Phase 2 / Phase 3 | Enrolling by invitation | Disc Medicine, Inc | 230 | 2023-08-31 | 2026-10-09 |
| Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency Alpha-1 MP - Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency | Phase 3 | Enrolling by invitation | Grifols Therapeutics LLC | 290 | 2016-07-01 | 2026-06-23 |
Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Liver Cirrhosis, Biliary (1) · Neoplasms (1) · Non-alcoholic Fatty Liver Disease (1) · Porphyrias (1) · Prostatic Neoplasms (1) · Protoporphyria, Erythropoietic (1) · Pulmonary Emphysema (1) · alpha 1-Antitrypsin Deficiency (1)
Digestive System Diseases (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Adenocarcinoma (1) · Bile Duct Diseases (1) · Biliary Tract Diseases (1) · Carcinoma (1) · Cholestasis (1) · Cholestasis, Intrahepatic (1) · Chronic Disease (1) · Colonic Diseases (1) · Digestive System Neoplasms (1)
Prednisone (2) · (4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone (1) · Mp alpha1 receptor (1) · Nivolumab (1) · Ursodeoxycholic Acid (1) · abiraterone (1) · atezolizumab (1) · cabozantinib (1) · enzalutamide (1)
Disc Medicine, Inc (1) · Exelixis (1) · Grifols Therapeutics LLC (1) · Han Ying (1) · Yoon Jun Kim (1)
United States (3) · Australia (2) · France (2) · Sweden (2) · Belgium (1) · Canada (1) · China (1) · Denmark (1) · Estonia (1) · Finland (1) · Germany (1) · Ireland (1) · Italy (1) · Moldova (1) · Netherlands (1)
Will Savage, MD PhD (1) · YoonJun Kim, MD.PhD (1)